同型半胱氨酸与缺血性脑血管病相关性及控制措施分析

目的探讨同型半胱氨酸(Hcy)与缺血性脑血管病(ICVD)的相关性及控制措施。方法选取ICVD患者85例为ICVD组,选取同期入院体检正常人40例为对照组,检测Hcy水平、叶酸、维生素B12;并观察ICVD患者服用叶酸、维生素B12、维生素B6前后Hcy、叶酸、维生素B12水平变化情况。结果脑梗死组Hcy(17.01±2.96)μmol/L显著高于TIA组、对照组,叶酸为(14.63±7.58)μg/L显著低于TIA、对照组,TIA组、对照组组间差异有统计学意义(P0.05);脑梗死组、TIA组B12水平均低于对照组,但脑梗死组、TIA组间差异无统计学意义(P0.05)。ICVD患者治疗后Hcy水平为(14.64±3.57)μmol/L,显著低于治疗前,叶酸、B12水平分别为(34.05±15.26)μg/L、(724.99±157.67)μmol/L,均显著高于治疗前,差异有统计学意义(P0.05)。结论高Hcy血症与ICVD具有显著相关性,可补充叶酸、B族维生素,降低血浆Hcy水平。     

高同型半胱氨酸血症与2型糖尿病脑梗死的关系及其影响因素的研究

目的　研究高同型半胱氨酸血症(HHcy)与2型糖尿病脑梗死之间的关系及其影响因素。方法　应用高效液相色谱分析方法测定2型糖尿病脑梗死组(DS组)、2型糖尿病无并发症组(DNC组)患者和正常对照组血Hcy浓度,放免方法测定各组的叶酸、维生素B12水平。结果　DS组、DNC组的Hcy水平和HHcy的发生率均显著高于正常对照组(均P<0 .05);DS组的Hcy水平及HHcy发生率显著高于DNC组(均P<0. 05)。单因素相关分析显示2型糖尿病患者血中Hcy水平与体质量指数、尿素氮、肌酐(Cr)、糖化血红蛋白(HbAlc)、Cr清除率呈正相关(r=0 .455、0. 36、0. 48、0. 4,P<0 .05 ~0 .01),与叶酸、维生素B12水平呈负相关(r=-0. 21、-0 .34,均P<0 .05);多元逐步回归分析示维生素B12、HbAlc、Cr清除率和叶酸是影响Hcy水平的因素。结论　HHcy是2型糖尿病脑梗死的一个危险因素。2型糖尿病患者Hcy水平受维生素B12、叶酸、肾功能以及代谢紊乱程度的影响。     

青壮年缺血性脑血管病血清同型半胱氨酸水平的研究

目的　探讨血清同型半胱氨酸 (Hcy)水平与缺血性脑血管病的关系。方法　研究对象为青壮年缺血性脑血管病患者 182例 ,分为 3组 :短暂性脑缺血发作 (49例 )、脑梗死急性期 (74例 )和脑梗死恢复期 (5 9例 ) ,正常对照组 38例。应用高效液相色谱法 ,测定空腹血清同型半胱氨酸浓度 ,应用自动生化分析仪测定血糖、血脂 ;同时对脑梗死急性期患者进行病灶体积计算。采用 SPSS软件分析。结果　脑梗死急性期血清同型半胱氨酸水平显著高于脑梗死恢复期及短暂性脑缺血发作组 (P<0 .0 1) ;3组均明显高于对照组 (P<0 .0 5～ 0 .0 1) ;血清 Hcy水平与病灶体积大小呈正相关 (r=0 .4 5 ,P<0 .0 5 ) ;高血压、糖尿病和高脂血症病史与血清 Hcy水平无明显的相关。结论　高 Hcy血症可能为青壮年缺血性脑血管病发病的独立危险因素 ,且血清同型半胱氨酸水平能反映脑梗死急性期病灶的大小。     

高同型半胱氨酸血症与颅内外血管狭窄的相关性研究

目的 探讨缺血性脑血管病患者高同型半胱氨酸(Hcy)血症与颅内外血管狭窄的关系.方法 应用全自动生化分析仪,用循环酶法检测405例缺血性脑血管病患者血清Hcy水平,同时检测血清叶酸、维生素B12水平,应用经颅多普勒(TCD)检测所有患者的颅内血管,应用双功能彩色多普勒检测颅外血管.根据检测结果将颈内动脉(ICA)分为:正常、轻度狭窄(＜50%)、中度狭窄(50%～69%)、重度狭窄(70%～99%)、闭塞;大脑中动脉(MCA)分为:正常、中度狭窄(50%～69%)、重度狭窄(70%～95%)、极度狭窄(＞95%).结果 有颅内外血管狭窄组血清Hcy水平显著高于无颅内外血管狭窄组(P<0.01),血清叶酸水平显著低于无颅内外血管狭窄组(P<0.05),血清维生素B12水平两组间差异无统计学意义(P>0.05);ICA、MCA不同程度狭窄患者间血清Hcy水平差异有统计学意义(均P<0.01),血清叶酸水平差异有统计学意义(均P<0.05),维生素B12水平差异无统计学意义(均P>0.05);Hcy水平与ICA、MCA狭窄程度呈正相关(r=0.356 ,P<0.01;r=0.345 ,P<0.01);血清叶酸水平与ICA、MCA狭窄程度呈负相关(r=-0.272 ,P<0.05;r=-0.265,P<0.05).结论 高Hcy血症与颅内外血管狭窄程度密切相关,高Hcy血症可能是缺血性脑血管病新的危险因素.     

脑梗死患者血清同型半胱氨酸与颈动脉硬化关系的研究

目的研究脑梗死患者血清同型半胱氨酸(homocysteine,Hcy)水平及其与颈动脉硬化的关系。方法收集230例脑梗死患者、180例健康对照者血液标本,采用荧光偏振免疫法测定Hcy、叶酸和维生素B12及酶法测定血脂水平。同时对165例患者作颈动脉超声检查并按动脉硬化的程度分组,比较不同程度颈动脉硬化组血清Hcy水平变化。结果脑梗死组患者血清Hcy水平显著高于对照组(P<0.05),血清Hcy与叶酸,维生素B12呈明显负相关(P<0.05),随着颈动脉病变程度加重血清Hcy水平呈上升趋势,且高Hcy检出率增高。结论高Hcy血症是脑梗死的独立危险因素,与颈动脉硬化程度有关,高血Hcy水平的主要原因可能与缺乏叶酸、维生素B12有关。     

高同型半胱氨酸血症与卒中的关系

目的 探讨高同型半胱氨酸（Homocysteine,Hcy）血症与卒中的关系。方法 选择卒中患者102例（66例脑梗死和36例脑出血）为卒中组,与病例组年龄、性别、种族等相匹配的未患过卒中来院进行健康体检者102例为对照组。采用高效液相色谱荧光检测法测定两组的血清Hcy水平。同时检测叶酸、维生素B12、血糖、血脂等。结果 卒中组血清Hcy水平显著高于对照组（20±9μmol/L vs 9±6μmol/L,P<0.01）;脑梗死和脑出血患者的血清Hcy水平无统计学差异（P>0.05）;血清叶酸及维生素B12水平与血清Hcy均呈负相关;Logistic回归分析显示,高Hcy血症卒中的独立危险因素（OR 4.875,95%CI 1.902～8.552,P<0.05）。结论 高Hcy血症是卒中的独立危险因素;叶酸和VitB12的缺乏可能是导致高Hcy血症的原因之一。     

血浆同型半胱氨酸水平及其代谢酶N5,N10亚甲基四氢叶酸脱氢还原酶基因多态性与Binswanger病的关系

目的探讨血浆同型半胱氨酸(Hcy)水平及其相关代谢酶N5,N10亚甲基四氢叶酸脱氢还原酶(MTHFR)基因多态性与Binswanger病(BD)的关系。方法应用荧光极化免疫法测定77例BD患者和71名健康体检者(健康对照组)的血浆Hcy水平,采用多聚酶链反应限制性片段长度多态性检测MTHFR基因C677T多态性。结果BD组患者血浆Hcy水平为(19.83±2.23)μmol/L,显著高于健康对照组的(13.03±3.79)μmol/L(P<0·01)。BD组和健康对照组间MTHFR各基因型分布和等位基因频率比较差异无显著性(均P>0·05)。各基因型之间血浆Hcy含量差异亦无显著性(均P>0·05)。结论BD患者血浆Hcy水平明显高于健康人,高Hcy血症可能参与了BD的发病过程;而MTHFR基因多态性与BD可能无明显关系。     

同型半胱氨酸与阿尔茨海默病及血管性痴呆

目的研究同型半胱氨酸(Homocysteine,Hcy)及叶酸、维生素B_(12)与阿尔茨海默病(Alzheimer Dis- ease,AD)和血管性痴呆(Vascular dementia,VaD)的关系,并通过Hcy揭示AD发病的血管危险因素。方法用美国国立神经病学、语言障碍和卒中-阿尔茨海默病和相关疾病学会(NINCDS-ADRDA)标准的可能标准严格筛选AD患者35例,用ADDTC诊断标准筛选VaD患者30例,并同期选择31例无临床脑血管病史、无认知功能障碍的健康查体中心志愿者为对照组。取肝素抗凝的血浆用循环酶法进行Hcy的测定。取血清由全自动化学发光免疫检测仪进行叶酸和维生素B_(12)的测定。结果AD组和VaD组血浆Hcy水平显著高于对照组,血清叶酸和VitB_(12)水平显著低于对照组。VaD组存在痴呆程度越高血浆Hcy水平越高这一显著正相关关系,而AD组这一正相关关系无统计学意义;且发现VaD组患者MMSE评分越低其血浆Hcy水平越高这一显著负相关关系,而AD组这一关系仍无统计学意义。在所有研究对象中存在血浆Hcy水平与血清叶酸及VitB_(12)水平的显著负相关关系。结论提示高Hcy血症可能是引起AD和VaD的一个重要危险因素,Hcy作为一个新的血管因素加强了AD与血管危险因素之间的联系,并且提示积极治疗高Hcy血症在预防AD和VaD方面可能有积极意义。     

脑梗死患者血浆硫化氢、同型半胱氨酸、叶酸和维生素B6水平的改变及其相关性

目的 探讨脑梗死患者血浆硫化氢、同型半胱氨酸(Hcy)、叶酸和维生素B6水平的变化及其相关性.方法 检测60例脑梗死患者和40名正常对照者血浆硫化氢、Hcy、叶酸及维生素B6水平.脑梗死患者血浆硫化氢水平与Hcy、叶酸和维生素B6水平的相关性采用直线相关分析.结果 与正常对照组比较,脑梗死组血浆Hcy水平显著增高,血浆硫化氢、叶酸、维生素B6水平显著降低(P<0.05～0.001).血浆硫化氢水平与Hcy水平呈负相关(r=-0.6271,P<0.01),与叶酸及维生素B6水平呈正相关(r=0.5341,P<0.005;r=0.4615,P<0.05).结论 脑梗死患者血浆硫化氢、叶酸和维生素B6水平明显降低,Hcy水平升高.血浆低硫化氢水平可能参与了高Hcy血症致脑血管病的发病机制,可能是脑血管病的危险因素.     

血浆同型半胱氨酸与脑卒中的关系

目的:探讨血浆同型半胱氨酸(Hcy)与脑卒中的关系。方法:采用微粒子酶免分析(MEIA)测定130例脑卒中患者(急性脑梗死90例、脑出血40例)和80例对照组血浆Hcy浓度,同时测定叶酸、维生素B12、血脂、空腹血糖等,进行Logistic回归分析。结果:卒中组平均血浆Hcy水平[(16.71±6.93)μmol·L-1]明显高于对照组「(10.16±2.71)μmol·L-1](t=8.07,P<0.001);两组中血浆Hcy升高分别有60例(46.15%)和5例(6.25%),差异有显著统计学意义(χ2=36.898,P<0.001)。卒中组平均血浆叶酸水平及维生素B12明显低于对照组;两组血浆Hcy浓度与叶酸及维生素B12水平均呈负相关。Hcy浓度与血压、血糖、血脂、尿酸无明显相关性。Logistic回归分析显示,高Hcy血症的OR值为5.272(95%CI:2.406￣11.552)。结论:高Hcy血症是脑卒中的独立危险因素;Hcy与叶酸、维生素B12呈负相关。     

血浆同型半胱氨酸与缺血性脑血管病临床表现的相关性分析

目的探讨血浆同型半胱氨酸(Hcy)水平与缺血性脑血管病的关系及其与疾病临床表现严重程度的关系。方法酶联免疫吸附法检测90例脑梗死患者,44例短暂性脑缺血发作(TIA)患者和40例同期门诊体检者(对照组)血浆Hcy水平并记录脑血管病患者的传统危险因素;对脑梗死组患者进行神经系统功能缺损评分(NIHSS)。分析血浆Hcy与缺血性脑血管病的关系及其与缺血性脑血管病的部分类型以及病情严重程度的相关性。结果缺血性脑血管病组、脑梗死组与TIA组患者血浆Hcy水平均高于对照组(P<0.05),脑梗死与TIA患者血浆Hcy水平相比较差异无统计学意义(P>0.05);血浆Hcy水平与NIHSS评分无明显相关性(r=0.155,P=0.323);采用多因素Logistic回归分析,血浆Hcy进入模型。结论血浆Hcy水平升高可能是与传统危险因素无关的缺血性脑血管病的独立危险因素,但Hcy水平与其类型及临床表现严重程度无关。     

Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine

OBJECTIVE: To evaluate plasma homocysteine (Hcy) concentrations in children receiving sodium valproate (VPA) and carbamazepine (CBZ), monotherapy, in comparison with healthy control subjects and to determine the possible relationship between Hcy levels and dosage and plasma concentrations of the antiepileptic drugs. METHODS: We measured levels of fasting and post-methionine Hcy, plasma pyridoxal 5'-phosphate (PLP, active vitamin B6), serum folate, erythrocyte folate and serum vitamin B12 in 60 epileptic patients (29 females, 31 males), aged from 14.2 to 17.9 years, subdivided into two groups according to their therapy. Sixty-three healthy sex- and age-matched children served as controls. These measurements have been performed before the beginning of therapy and after 1 year of therapy with VPA or CBZ. RESULTS: Before the beginning of therapy, there were no significant differences in fasting and post-methionine Hcy, plasma PLP, serum folate, erythrocyte folate and serum vitamin B12 values between the control group and the two groups of epileptic children. After 1 year of therapy, patients treated with VPA and CBZ showed a significant increase of the plasma concentrations of Hcy when compared to baseline data and controls values. Moreover, was observed a significant decrease of serum folate and plasma PLP. On the contrary, serum vitamin B12 and erythrocyte folate levels remained in the normal range. CONCLUSIONS: Our study demonstrates that prolonged treatment with VPA and CBZ increases plasma concentrations of Hcy.     

精神分裂症血浆硫化氢、同型半胱氨酸、叶酸及维生素B6水平研究

目的:探讨精神分裂症患者血浆硫化氢(H2S)、同型半胱氨酸(Hcy)、叶酸(FA)和维生素B6(VitB6)水平的变化及其相关性.方法:检测66例精神分裂症患者和50名健康对照者的血浆H2S、Hcy、FA及VitB6水平.精神分裂症患者血浆H2S水平与Hcy、FA和VitB6水平的相关性用直线相关分析.结果:与正常对照...     

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.

Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). The mechanism underlying HHcy in PD is the O-methylation of levodopa catalyzed by catechol-O-methyltransferase (COMT) that produces S-adenosylhomocysteine, which is hydrolyzed rapidly to Hcy. COMT inhibitors (COMT-I) are used currently in the treatment of PD; however, no study has assessed the effects of COMT-I administration on Hcy concentrations in PD patients. We compared plasma levels of Hcy, B12, and folate in 26 PD patients treated with levodopa, 20 PD patients treated with levodopa + COMT-I, and 32 controls. No significant differences were found in vitamin B12 levels, whereas folate concentrations were significantly lower in the levodopa-treated group. Plasma Hcy was increased significantly in the two groups of PD patients and was significantly lower in the group treated with levodopa + COMT-I. Statistical analysis showed that the difference in mean Hcy levels observed among PD patients was related to the addition of COMT-I, rather than to folate concentrations. We conclude that levodopa treatment increases plasma Hcy and the addition of COMT-I effectively reduces HHcy.     

Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia

High levels of homocysteine (Hcy) were suggested to contribute to the pathogenesis of schizophrenia. Recent investigations have shown that treatment with folic acid, vitamin B-12 and pyridoxine are effective in reducing Hcy levels while concomitantly reducing the score of positive and negative symptoms in schizophrenic patients. In addition to the availability of nutrients (mainly folate, vitamins B6 and B12), plasma Hcy concentrations are dependent on complex metabolic regulation that could be disrupted in schizophrenia.This study was designed to test the influence of disease activity on plasma Hcy levels. Plasma Hcy concentrations were measured in male chronic schizophrenic patients with a predominantly positive (SCH (+)) or predominantly negative (SCH (−)) syndrome in schizophrenia immediately upon admission to the hospital (exacerbation phase) and one month later (remission phase). During this period patients received antipsychotic medications without vitamin therapy. The effects of age, duration of illness, folate and B12 concentrations, as well as smoking and coffee consumption habits on the observed changes were evaluated. Age- and sex-matched subjects were included in the control group. In the control group plasma Hcy concentration was 8.75 ± 1.84 μmol/L. In the exacerbation phase plasma Hcy concentrations were significantly increased both in SCH (+) (14.91 ± 6.19 μmol/L) and SCH (−) groups (12.8 ± 3.27 μmol/L). There was no difference in plasma Hcy concentrations between SCH (+) and SCH (−) patients. Serum folate and B12 concentrations were not significantly different in any of the investigated groups of subjects. The plasma Hcy concentrations could not be correlated with age, duration of illness, the score of positive symptoms or the concentration of folate and vitamin B12. A positive correlation was found between plasma Hcy level and score of negative symptoms in both groups of patients. No correlation was found between smoking or coffee consumption habits and plasma Hcy concentrations. All patients exhibited decreased plasma Hcy levels in the remission phase of the illness, with a mean decrease of 2.68 ± 1.57 μmol/L. Folate and B12 levels did not differ in the exacerbation and remission phases of the illness.The significant decrease of plasma Hcy levels, without changes in folate and vitamin B12 concentrations in the remission phase of schizophrenia, could indicate an influence of a pathogenetic process involved in schizophrenia on Hcy metabolism.     

The effect of C677T mutation of methylene tetrahydrofolate reductase gene and plasma folate level on hyperhomocysteinemia in patients with meningomyelocele

To evaluate the relationship between genotypes of methylene tetrahydrofolate reductase (MTHFR), and plasma folate and homocysteine (Hcy) levels in meningomyelocele, 21 Korean patients, 47 of their family members, and 43 healthy controls were recruited. The presence of C677T mutation in the MTHFR gene and plasma concentrations of folate/Hcy were investigated. The genotype frequency of C677T mutation was not higher in study groups (patients and family members). The plasma folate concentration showed no difference either between the study and the control groups or among MTHFR-genotypic groups. The plasma Hcy concentration in homozygotes in the study group was higher than that in the control group, and higher than that in heterozygotes when plasma folate levels were low (P=0.006). Although neither MTHFR genotype nor plasma folate/Hcy level plays a definite part on its own, they seem to have an additive effect on the occurrence of meningomyelocele. Our results support folate supplementation for the prevention of hyperhomo- cysteinemia and meningomyelocele. Received: 11 November 1999 Revised: 3 April 2000     

伴有阻塞性睡眠呼吸暂停低通气综合征的缺血性脑血管病患者血同型半胱氨酸的变化

目的 探讨伴有阻塞性睡眠呼吸暂停低通气综合征(obstructive sleep apnea-hypopnea syndrome,OSAHS)的缺血性脑血管病患者(ischemie cerebrovascular disease,ICVD)血同型半胱氨酸(homocysteine,Hey)水平.方法 从南京脑卒中注册系统中筛选76例ICVD患者,行多导睡眠图(PSG)监测,并检测纤维蛋白原(FBG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、血浆Hcy.结果 76例患者中有57例存在呼吸暂停现象,其中53例(69.7%)诊断为OSAHS;排除4例中枢性呼吸暂停患者,将72例ICVD患者根据呼吸暂停加低通气指数(AHI)值分为4组:无呼吸暂停组19例,AHI值2.38±0.96,Hcy值(8.78±2.01)μmol/L;轻度OSAHS 21例,AHI值14.14±4.37,Hcy值(12.91±3.00)μmoL/L;中度OSAHS24例,AHI值29.62±5.81,Hcy值(14.85±4.15)μmoL/L;重度OSAHS 8例,AHI值46.75±2.82,Hey值(19.30±4.82)μmoL/L.4组间Hcy值差异有统计学意义(F=40.32,P<0.01).Hey与AHI存在显著相关性(r=0.598,P<0.01).结论 在ICVD患者中,OSAHS患病率较高,且以轻中度为主;Hcy在ICVD合并OSAHS患者时具有升高趋势,且随着阻塞程度的进展而加重.     

Mild hyperhomocysteinemia and low folate concentrations as risk factors for cervical arterial dissection

BACKGROUND AND PURPOSE: Elevated homocysteine (Hcy) plasma levels are associated with an increased risk of spontaneous cervical artery dissection (sCAD). We examined the potential association between Hcy, folate, vitamin B(12) levels and 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms in patients with cerebral infarct caused by sCAD. PATIENTS AND METHODS: 39 patients who survived a cerebral infarct caused by sCAD [20 (51%) women; 24 (61.5%) vertebral and 15 (38.5%) internal carotid arteries], and 76 healthy control subjects were included. Hcy plasma levels (fasting and after methionine load), folate and vitamin B(12) levels were measured. We also performed polymorphisms of MTHFR. Hcy, vitamin B(12), folates and polymorphisms of MTHFR were assessed and any associations were analyzed using multivariate statistics. RESULTS: Mean plasma fasting Hcy level was 9.81 mumol/l for cases and 6.38 for controls (p = 0.001). The occurrence of sCAD was associated with elevated fasting Hcy levels (>95th percentile over the control group) with an adjusted odds ratio of 7.9 (95% CI 1.66-35). The association between low plasma folate values (<5th percentile) and the presence of CAD was 7.9 (95% CI 1.6-31) after adjusting for confounding variables. The distribution of the MTHFR genotype showed a higher TT mutant frequency among CAD patients (p = 0.034). CONCLUSIONS: High plasma concentrations of Hcy and low plasma levels of folate were associated with an increased risk of sCAD in the sample studied. We conclude that deficiencies in nutritional status may contribute to the relatively high incidence of CAD in Mexico.     

Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson’s Disease Patients

There is evidence that increased homocysteine (Hcy) levels might accelerate dopaminergic cell death in Parkinson's disease (PD) through neurotoxic effects. Homocysteine neurotoxicity mainly relies on redox state alterations. The present work was aimed at investigating the relationships between plasma Hcy concentrations and percent content of oxidized versus total Coenzyme Q10 (%CoQ10) in 60 PD patients and 82 healthy subjects. Both groups were screened for plasma levels of Hcy, vitamin B12, folate, %CoQ10 and C677T methylenetetrahydrofolate reductase (MTHFR) gene polymorphism. The MTHFR TT677 mutated genotype was found more frequently in patients than in controls (p = 0.01). In a multivariate analysis, Hcy levels and %CoQ10 were associated with the case/control category (p < 0.0001), MTHFR genotype (p < 0.0001) and their interaction term (p = 0.0015), even after adjusting for age, sex, folate and vitamin B12. Patients carrying the TT677 genotype exhibited the highest values of Hcy and %CoQ10 (p < 0.0001). Structural equation modelling evidenced that the TT677 genotype and levodopa daily dose were independently and directly correlated with Hcy (p < 0.0001, and p = 0.003, respectively), which, in turn, showed a significant correlation (p < 0.0001) with the %CoQ10 in PD patients. Our results suggest that increased Hcy levels act as mediator of the systemic oxidative stress occurring in PD, and %CoQ10 determination might be regarded as a predictor of toxic Hcy effects.     

血浆同型半胱氨酸水平及MTHFR基因多态与血管性痴呆的关系

目的探讨血浆同型半胱氨酸(H cy)水平及M THFR基因多态与血管性痴呆(VD)的关系。方法应用高效液相色谱仪和电化学检测法测定37例VD患者的血浆总H cy水平,并与40例同龄对照组及40例非痴呆脑梗死组比较,运用多聚酶链反应-限制性内切酶片段长度多态性技术(PCR-RFLP)检测M THFR基因多态性,同时测定血浆叶酸及维生素B12水平。结果VD患者血浆总H cy水平显著高于同龄对照组(P<0.001)和非痴呆脑梗死组(P<0.05);M THFR基因型有3种,即纯合子(T/T)型,杂合子(T/C)型,纯合子(C/C)型。3组基因型和等位基因频率相比,差异均无显著性(P>0.05);VD组血浆叶酸及维生素B12水平明显低于同龄对照组(P<0.05)和非痴呆脑梗死组(P<0.05)。结论高同型半胱氨酸血症是VD发病的一个新的危险因素。